Company Snapshot

Investment Thesis

Vertex transformed cystic fibrosis care and is extending its genetic medicine toolkit into pain, kidney disease, and gene-editing cures. Durable CF cash flows fund late-stage programs such as VX-548, inaxaplin, and the CRISPR-based exa-cel therapy.

  • CF Franchise Depth: Trikafta/Kaftrio penetration, younger patient cohorts, and geographic expansion sustain growth.
  • Pipeline Convergence: Non-opioid pain, APOL1 kidney disease, and type 1 diabetes programs diversify revenue.
  • Balance Sheet Strength: Net cash and disciplined BD allow co-development deals without diluting shareholders.

Strategic Mix

Cystic Fibrosis Modulators addressing 90%+ of the CF population
Gene Editing & Cell Therapy exa-cel with CRISPR Therapeutics; stem-cell derived islet cells
Small Molecule Pipeline Non-opioid pain (VX-548) and kidney disease (inaxaplin)
Platform Investments mRNA, lipid nanoparticle, and delivery technologies via collaborations

Mix aligns with Vertex’s 2024 outlook and disclosed pipeline priorities.

Recent Performance

MTD TBD
QTD TBD
YTD TBD
5Y TBD

Maxim is cueing up returns data for this security. Once the nightly supported.csv job runs, these metrics will auto-populate.

Strategic Insights

Label Expansion

Younger age approvals and reimbursement broaden the CF patient base.

Regulatory Cadence

Simultaneous U.S./EU filings for VX-548 and exa-cel create multiple catalysts through 2025.

Manufacturing Scaling

In-house cell therapy capacity and digital supply chains reduce future COGS.

Latest Coverage

Curated headlines sourced from Maxim’s AI newsroom.

Loading latest coverage...